Clinical Scorecard: When Inflammation Fuels Cancer in the IBD Colon

At a Glance

Key Highlights

• TL1A activates type 3 innate lymphoid cells (ILC3s) leading to increased neutrophil production.
• Neutrophils generated during chronic inflammation differ from those in acute infection.
• Dysplastic lesions in IBD show increased expression of tumor-promoting neutrophil-related genes.
• Blocking TL1A signaling reduces tumor burden in mouse models.
• Anti-TL1A therapy in ulcerative colitis patients reduces neutrophil-associated gene expression.

Guideline-Based Recommendations

Diagnosis

• Assess immune gene signatures in chronically inflamed tissue.
• Differentiate between harmful and protective neutrophil populations.

Management

• Consider anti-TL1A therapy for patients with severe IBD.
• Monitor for dysplastic lesions in IBD patients.

Monitoring & Follow-up

• Use immune and spatial profiling approaches to assess cancer risk.

Risks

• Increased risk of colorectal cancer in patients with long-standing IBD.

Patient & Prescribing Data

Patients with inflammatory bowel disease (IBD), particularly those with ulcerative colitis.

Anti-TL1A therapy may reduce tumor-promoting neutrophil activity.

Clinical Best Practices

• Regularly monitor IBD patients for signs of dysplasia.
• Utilize immune profiling to guide treatment decisions.

References

• Immunity Study on IBD and Colorectal Cancer